IL143772A0 - Synergistic tumorcidal response induced by histamine - Google Patents

Synergistic tumorcidal response induced by histamine

Info

Publication number: IL143772A0
Authority: IL; Israel
Prior art keywords: histamine; response induced; tumorcidal response; synergistic; synergistic tumorcidal
Prior art date: 1999-01-06

Application number

IL14377200A

Other languages

English (en)

Original Assignee

Maxim Pharm Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-01-06

Filing date

2000-01-04

Publication date

2002-04-21

2000-01-04 Application filed by Maxim Pharm Inc filed Critical Maxim Pharm Inc

2002-04-21 Publication of IL143772A0 publication Critical patent/IL143772A0/xx

Links

NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 title 2
229960001340 histamine Drugs 0.000 title 1
230000002195 synergetic effect Effects 0.000 title 1
230000002476 tumorcidal effect Effects 0.000 title 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
- A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Mycology (AREA)
Microbiology (AREA)
Oncology (AREA)
Hematology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

IL14377200A 1999-01-06 2000-01-04 Synergistic tumorcidal response induced by histamine IL143772A0 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US09/226,226 US6498181B1 (en)	1999-01-06	1999-01-06	Synergistic tumorcidal response induced by histamine
PCT/US2000/000094 WO2000040229A2 (en)	1999-01-06	2000-01-04	Synergistic tumorcidal response induced by histamine

Publications (1)

Publication Number	Publication Date
IL143772A0 true IL143772A0 (en)	2002-04-21

Family

ID=22848072

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL14377200A IL143772A0 (en)	1999-01-06	2000-01-04	Synergistic tumorcidal response induced by histamine

Country Status (11)

Country	Link
US (3)	US6498181B1 (de)
EP (1)	EP1140290A2 (de)
JP (1)	JP2002534378A (de)
KR (1)	KR20010101379A (de)
CN (1)	CN1342096A (de)
AU (2)	AU768868B2 (de)
CA (1)	CA2358754A1 (de)
HK (1)	HK1040204A1 (de)
IL (1)	IL143772A0 (de)
WO (1)	WO2000040229A2 (de)
ZA (1)	ZA200104997B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7361336B1 (en)	1997-09-18	2008-04-22	Ivan Bergstein	Methods of cancer therapy targeted against a cancer stem line
US6498181B1 (en) *	1999-01-06	2002-12-24	Maxim Pharmaceuticals	Synergistic tumorcidal response induced by histamine
WO2000067796A1 (en)	1999-05-07	2000-11-16	Genentech, Inc.	Treatment of autoimmune diseases with antagonists which bind to b cell surface markers
KR20020027490A (ko) *	1999-07-12	2002-04-13	제넨테크, 인크.	Ｃｄ20에 결합하는 길항제를 사용한 외래 항원에 대한면역 반응 차단 방법
AU779215B2 (en) *	1999-07-16	2005-01-13	Maxim Pharmaceuticals, Inc.	Activation and protection of cytotoxic lymphocytes using a reactive oxygen metabolite inhibitor
US6949243B1 (en) *	1999-11-24	2005-09-27	Schering Corporation	Methods of inhibiting metastasis
US7534417B2 (en) *	2000-02-24	2009-05-19	Agensys, Inc.	103P2D6: tissue specific protein highly expressed in various cancers
CU22979A1 (es) *	2000-12-08	2004-09-09	Centro Inmunologia Molecular	Combinación inmunoterapéutica para el tratamiento de tumores que sobre-expresan receptores con actividad quinasa en residuos de tirosina
BR0308976A (pt) *	2002-04-02	2005-01-11	Pharmacia Italia Spa	Terapia combinada contra tumores compreendendo derivados de acriloil distamicina substituìda e radioterapia
US20070037825A1 (en) *	2002-07-19	2007-02-15	Janina Baranowska-Kortylewicz	Enhancing the effect of radioimmunotherapy in the treatment of tumors
AU2011347327A1 (en) *	2010-12-22	2013-07-18	Ifom Fondazione Istituto Firc Di Oncologia Molecolare	uPAR-antagonists and uses thereof
US10485470B2 (en)	2015-02-03	2019-11-26	Quantalx Neuroscience Ltd	Early diagnosis and treatment of Alzheimer disease and mild cognitive impairment
WO2017137989A1 (en) *	2016-02-08	2017-08-17	Immune Pharmaceuticals Ltd.	Histamine dihydrochloride combinations and uses thereof
WO2019023263A1 (en) *	2017-07-25	2019-01-31	Immune Pharmaceuticals, Inc.	METHODS AND COMPOSITIONS FOR TREATING TUMORS COMPRISING A BCR-ABL1 FUSION GENE
JP2021500374A (ja)	2017-10-24	2021-01-07	ルネラ・バイオテック・インコーポレーテッド	標的フラビン含有酵素がミトコンドリア呼吸を阻害することにより癌幹細胞（ｃｓｃｓ）を排除するミトフラボスチン
WO2020123194A1 (en) *	2018-12-11	2020-06-18	Kristoffer Hellstrand	Methods of reducing post-surgical metastasis

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4886665A (en)	1987-03-11	1989-12-12	Arcopharma Ltd.	Compositions of oats and nettle extracts to be used as a food additive or pharmaceutical preparation in human health care
CA2066728C (en)	1989-09-19	2001-12-25	Jan K. Hellstrand	Anti-tumor preparation comprising interleukin-2 and histamine, analogs thereof or h2-receptor agonists
US5618846A (en)	1990-12-17	1997-04-08	University Of Manitoba	Treatment method for cancer
US5798339A (en)	1990-12-17	1998-08-25	University Of Manitoba	Treatment method for cancer
CN1079908A (zh)	1992-01-26	1993-12-29	伊姆罗吉制药公司	组胺衍生物及其用作免疫调节剂的方法
SE513429C2 (sv)	1992-06-03	2000-09-11	Syntello Inc	Preparat för aktivering av naturliga mördarceller, vilket preparat innehåller interferon alfa och biogena aminer
EP0646019B9 (de) *	1992-06-09	2002-12-18	Neorx Corporation	Biotin-DOTA Konjugate und deren Verwendung in "Pretargeting" Verfahren
US5843979A (en) *	1993-02-25	1998-12-01	Bristol-Myers Squibb Company	Transdermal treatment with mast cell degranulating agents for drug-induced hypersensitivity
US5432168A (en)	1993-12-27	1995-07-11	University Of Manitoba	Method of treatment of hormone-unresponsive metastatic prostate cancer
US5478211A (en) *	1994-03-09	1995-12-26	Baxter International Inc.	Ambulatory infusion pump
CA2196756A1 (en)	1994-08-08	1996-02-22	Jan Urban Kristoffer Hellstrand	Enhanced activation of natural killer cells using an nk cell activator and a hydrogen peroxide scavenger or inhibitor
GB9416321D0 (en)	1994-08-12	1994-10-05	Peptide Therapeutics Ltd	Peptides and antibodies and their use in treatment of carcinomas
US5780435A (en)	1995-12-15	1998-07-14	Praecis Pharmaceuticals Incorporated	Methods for treating prostate cancer with LHRH-R antagonists
US5961969A (en) *	1996-05-14	1999-10-05	Maxim Pharmaceuticals, Inc.	Stable circulating histamine levels
US6498181B1 (en) *	1999-01-06	2002-12-24	Maxim Pharmaceuticals	Synergistic tumorcidal response induced by histamine

1999
- 1999-01-06 US US09/226,226 patent/US6498181B1/en not_active Expired - Lifetime
2000
- 2000-01-04 IL IL14377200A patent/IL143772A0/xx unknown
- 2000-01-04 HK HK02101636.6A patent/HK1040204A1/zh unknown
- 2000-01-04 AU AU33435/00A patent/AU768868B2/en not_active Ceased
- 2000-01-04 CN CN00804524A patent/CN1342096A/zh active Pending
- 2000-01-04 JP JP2000591986A patent/JP2002534378A/ja active Pending
- 2000-01-04 EP EP00911556A patent/EP1140290A2/de not_active Withdrawn
- 2000-01-04 WO PCT/US2000/000094 patent/WO2000040229A2/en not_active Ceased
- 2000-01-04 CA CA002358754A patent/CA2358754A1/en not_active Abandoned
- 2000-01-04 KR KR1020017008517A patent/KR20010101379A/ko not_active Ceased
2001
- 2001-06-19 ZA ZA200104997A patent/ZA200104997B/en unknown
2002
- 2002-08-09 US US10/217,254 patent/US20020193416A1/en not_active Abandoned
2004
- 2004-04-07 AU AU2004201486A patent/AU2004201486A1/en not_active Abandoned
- 2004-06-02 US US10/859,802 patent/US20040219153A1/en not_active Abandoned

Also Published As

Publication number	Publication date
WO2000040229A3 (en)	2001-07-19
US20040219153A1 (en)	2004-11-04
US20020193416A1 (en)	2002-12-19
AU768868B2 (en)	2004-01-08
JP2002534378A (ja)	2002-10-15
US6498181B1 (en)	2002-12-24
CA2358754A1 (en)	2000-07-13
HK1040204A1 (zh)	2002-05-31
EP1140290A2 (de)	2001-10-10
AU3343500A (en)	2000-07-24
ZA200104997B (en)	2002-05-10
CN1342096A (zh)	2002-03-27
AU2004201486A1 (en)	2004-05-06
KR20010101379A (ko)	2001-11-14
WO2000040229A2 (en)	2000-07-13

Publication	Publication Date	Title
EP1206262A4 (de)	2003-01-02	Neuropeptid-y antagonisten: derivate des spiroisoquinolinons
GB2349091B (en)	2003-06-18	Defibrillator
EG23817A (en)	2007-09-19	4-Phenyl-pyridine derivatives
GC0000183A (en)	2006-03-29	3-Phenyl-pyridine derivatives
GC0000338A (en)	2007-03-31	5-Phenyl-pyrimidine derivatives
IL145739A0 (en)	2002-07-25	13-methyl-erythromycin derivatives
IL143772A0 (en)	2002-04-21	Synergistic tumorcidal response induced by histamine
IL148058A0 (en)	2002-09-12	Substituted 2-dialkylaminoalkylbiphenyl derivatives
GB9930570D0 (en)	2000-02-16	Therapy
GB9907243D0 (en)	1999-05-26	Therapy
GC0000191A (en)	2006-03-29	4-Phenyl-pyrimidine derivatives
GC0000256A (en)	2006-11-01	Ethanesulfonyl-piperidine derivatives
GB9925880D0 (en)	1999-12-29	B-Carboline derivatives
AP2001002327A0 (en)	2001-12-31	1-Trifluoromethyl-4-hydroxy-7- piperidinylaminomethy lchroman derivatives
ZA200110046B (en)	2003-03-06	Therapeutic agents.
PL351671A1 (en)	2003-05-19	Substituted n-cyano amidines
GB9909532D0 (en)	1999-06-23	Disable multi-exercise
GB9923681D0 (en)	1999-12-08	Protection sub
GB9922935D0 (en)	1999-12-01	Protection sub
GB2348368B (en)	2002-10-09	Bedding set
GB9928738D0 (en)	2000-02-02	Pacemaker
GB9904754D0 (en)	1999-04-21	Body protection
ZA200204584B (en)	2004-06-30	Therapeutic agents.
GB9915092D0 (en)	1999-09-01	Easy fit er
GB9918351D0 (en)	1999-10-06	Well logging